cordycepin
Small moleculeexperimental
Cordycepin, or 3'-deoxyadenosine, is a derivative of the nucleoside adenosine, differing from the latter by the replacement of the hydroxy group in the 3' position with a hydrogen. It was initially extracted from the fungus Cordyceps militaris, but can now be produced synthetically. — Wikipedia
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 1997 (NCT00003005)
Timeline
1990s
- Jan 1, 1997
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)C[C@H]1O- Mol. weight
- 251.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCordycepin ↗
- ChEMBLCHEMBL5277528 ↗
- ChEMBLCHEMBL305686 ↗
Also known as
- 3'-deoxyadenosine
- cordycepin
- cordycepin
- cordycepin
- cordycepin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03829254 | Phase 1 | Feb 28, 2019 | Nucana |
| NCT00709215 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2008 | AAIPharma, Harvard University, OncoVista, Inc., University of Texas, San Antonio |
| NCT00003005 | Phase 1 | Dec 1, 1997 | Boston University, National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AAIPharma | For profit | 1 | 0 | 1 | 2008 |
| Boston University | Academic/Hospital | 1 | 1 | 1 | 1997 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1997 |
| Nucana | For profit | 1 | 1 | 1 | 2019 |
| OncoVista, Inc. | For profit | 1 | 1 | 1 | 2008 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 0 | 1 | 2008 |
7 organizations
Page 1 / 1